Two single-arm, open-label observational trials, which were designed to visualize subsurface tissue in patients undergoing esophagogastroduoenoscopy for suspected or confirmed Barrett’s esophagus, were conducted at the Mayo Clinic in Jacksonville, Florida, and Rochester, Minnesota, US.

The results showed that the NvisionVLE system’s high resolution and wide-field imaging enabled the detection of dysplasia that was missed with the standard biopsy protocol.

NinePoint Medical president and chief executive officer Charles said the initial data from the clinical trials show the potential benefit of NvisionVLE to image deeper into the tissue than has been possible with endoscopy alone.

"We are excited about these data presentations at ISDE, UEGW and ACG and we look forward to announcing the complete results of our clinical trial in Barrett’s esophagus soon," Carignan added.

In addition, the company is preparing for a commercial launch of the NvisionVLE system in the US and Europe in 2013.